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Abstract Breast cancer (BC) epidemic is recognised now
worldwide as the reality of the early twenty-first century.
Increasing trends in the postmenopausal BC prevalence, even
for the European countries earlier demonstrating relatively
stable incidence rates of the disease, are highly alarming for
the healthcare givers. This new actuality requires a substantial
revision of the paradigm currently applied to the BC manage-
ment and creation of highly innovative concepts. Current
multi-centred study highlights new complex mechanisms of
the development and progression of the postmenopausal BC.
Innovative concepts are presented which argue for more ef-
fective predictive and preventive approaches well justified in
view of the clusters of the symptoms analysed here and dem-
onstrated as highly prevalent in the postmenopausal breast
cancer versus BC-free individuals. Another conceptual novel-
ty presented here is a new interpretation of the BSeed and Soil^
theory of metastasis in BC. According to the new concept, the
Bpre-metastatic niches^ (BSoil^) are created by a systemic
hypoxia a long time before the breast malignancy is clinically
manifested.
Keywords Predictive preventive and personalisedmedicine .
Postmenopausal breast cancer .Metastatic disease . BSeed and
soil^ theory . Risk factors . Diabetes . Flammer syndrome .
Systemic hypoxia . Patient stratification . Cardiovascular
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Introduction
Postmenopausal breast cancer as the European challenge
Breast cancer (BC) epidemic is recognised now worldwide as
the reality of the early twenty-first century [1]. Moreover, in
the Eastern and Central European countries, amongst the four
most common cancers, specifically the postmenopausal breast
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cancer started to approach the incidence levels earlier regis-
tered for the Northern and Western Europe, where their rates
traditionally were the highest ones within the European area
[2]. Increasing trends in the postmenopausal breast cancer
prevalence, even for the European countries earlier demon-
strating relatively stable incidence rates of the disease, are
highly alarming for the healthcare givers. This new actuality
requires a substantial revision of the paradigm currently ap-
plied to the breast cancer management and creation of highly
innovative concepts, first of all, for the primary prevention of
breast cancer.
New concepts
By a series of recently published articles, we have introduced
highly promising concepts which strongly support the recog-
nition of the breast cancer pathology as the systemic disorder
and suggest innovative solutions in the context of predictive,
preventive and personalised medicine [3–5]. Herewith, we
briefly summarise the facts and findings which have motivat-
ed the current study.
Feeling cold and disturbed thermoregulation in BC
pathology
Compared to the general population, BC patients complain
more frequently about deficits in achieving thermal comfort
[3, 4]. They feel excessively hot or cold even in situations
when disease-free attendees are well comfortable with ambi-
ent temperature conditions [6]. The prevalence of both symp-
toms BFeeling inadequately cold^ and BCold extremities^ has
been demonstrated in breast cancer and metastatic disease
versus breast cancer-free individuals [4, 5].
Relevance of the cardiovascular component
Panels of biomarkers and symptoms have been investigated
demonstrating the cardiovascular component as being promi-
nently relevant for the development, progression and individ-
ual outcomes of the BC pathology [4, 5, 7].
Hypoxic effects and pre-metastatic niches
By evidence, both initial tumours and secondary metastases
need a Bfertile^microenvironment effectively supporting their
growth and progression [8]. Systemic hypoxic effects linked
to the cardiovascular component create this fertile microenvi-
ronment playing the central role in progressive BC and meta-
static disease [3, 9, 10]. Thereby, the appearance of the Bpre-
metastatic niches^ may occur prior to the tumour onset
resulting in the particularly aggressive metastatic disease de-
veloping at early stages of breast cancer [5].
Altered sense regulation
Panel of symptoms has been investigated indicating potential-
ly altered sense regulation as a component of the BC pathol-
ogy [4]. For example, underrepresented feeling of thirst may
result in strong body dehydration and disturbed detoxification
pathways, which in turn may cause significant toxic effects
increasing BC risks [3].
Drug sensitivity may be potentially altered in BC
Drug sensitivity is the major issue for individual outcomes in
treated BC. Potentially altered drug sensitivity in BC patients
has been indicated [4, 5].
Headache and BC risks
Headache is a controversially discussed BC risk factor. We
assume that a correct interpretation of the condition may de-
pend on the context and pathology-specific biomarker panels
to be applied [3–5].
Psychological patterns
Doubtlessly, psychological factors are important for the indi-
vidual outcomes in BC [1]. However, this area is currently
underdeveloped and clear patterns of the most relevant psy-
chological factors have not yet been created for predictive and
prognostic purposes in the overall breast cancer management.
Closing the gaps
In order to close the evident gaps in our current knowledge
listed above, our current study investigates the prevalence of
the individual symptoms of the BFlammer Syndrome^ (FS) in
the cohort of the postmenopausal breast cancer patients. FS
phenotype [11] is described for both healthy individuals in
sub-optimal health condition [12] and severely diseased pa-
tients [13]. FS is particularly relevant for females [11]. It is
characterised by local and systemic hypoxic effects caused by
vascular dysregulation [11] as well as molecular patterns
which are evidently relevant for the BC cancer advancement
[14–16] as described earlier.
Materials and methods
Flammer syndrome diagnostic approach
The Flammer syndrome (FS) phenotype has been
characterised earlier [11]. The FS-related questionnaire
utilised in the current study has been developed by the field-
dedicated research group at the University Hospital Basel in
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Switzerland. The actual version of the FS-specialised ques-
tionnaire has been successfully applied to several interna-
tional studies [17–22] and recently utilised for the multi-
centred pilot project focused on the breast cancer and
metastatic disease [4, 5].
Experimental design
For this study, the patients have been recruited and interviewed
by two specialised medical centres, the University Clinic of
Oncology and Radiotherapy, Skopje, Republic of Macedonia,
and Department of Obstetrics and Gynaecology, Jessenius
Faculty of Medicine, Martin University Hospital, Martin,
Slovak Republic. Both centres were involved in the internation-
al multi-centred study working in a tight collaboration with
other European partners participating in the project. The refer-
ence group comprising breast cancer-free individuals (BBC-free
reference^ patient cohort) has been created and interviewed by
the Slovakian partner organisation. The cohort of postmeno-
pausal breast cancer patients have been selected and
interviewed in the Republic of Macedonia. The partner organi-
sations of the international pilot project have elaborated both
the Bincluding^ and Bexcluding^ criteria for the study and
followed the same norms of ethics in accordance with the eth-
ical standards of the institutional and national research commit-
tees and with the international principles of the 1964 Helsinki
declaration and its later amendments.
Breast cancer-free reference cohort
The patient data-base available at the Department of
Obstetrics and Gynaecology, Jessenius Faculty of Medicine,
Martin University Hospital, Martin, Slovak Republic, has
been utilised for selecting the breast cancer-free individuals
as potential responders. Altogether, 73 breast cancer-free in-
dividuals have been recruited for this study as reported in the
original publication [4]. Following patient cohorts have been
included:
– Healthy individuals free of breast cancer and any other
malignancy (52 individuals of total)
– Benign breast fibro-adenoma (FIA), free of breast cancer
and any other malignancy (21 patients of total).
Selection and examination of healthy individuals
Healthy individuals have been clinically examined attesting
an absence of gynaecological problems and interviewed per-
sonally for the study during their hospital outpatient visit per-
formed in the framework of the national screening pro-
gramme. BC-free condition has been confirmed either by
breast sonography or mammography or both imaging
approaches. The examination reports used were not older than
6 months. Healthy individuals selected for this study demon-
strated no history of any previously diagnosed breast pathol-
ogy, no surgery performed due to breast lesions and no history
of any severe gynaecologic disease including cancer other
than breast malignancies or any systemic diseases such as
diabetes mellitus, rheumatic diseases and neurological disor-
ders. The entire methodological approach has been described
in the original publication [4].
Fibro-adenoma patients
Imaging technologies have been applied for the first choice of
the entire diagnostic procedure: digital mammography Hologic
system, 2D+ 3D sonography–VolusonUSG systemE8 and E10
machine, Birads 0–6 classification scoring system with double
reading of the radiologic approach. In case of reasonable
suspicion, the affected patients have undergone the biopsy
analysis (either core needle or Mammotome’s vacuum-
assisted). Histopathological analysis has, further, allowed for
distinguishing between BC malignancy and fibro-adenoma
(FIA) benignancy. FIA-individuals have been included into the
BC-free reference group of patients. The entire methodological
approach has been described in the original publication [4].
Breast cancer patient cohort
Breast cancer patients with and without metastases, treated at
the University Clinic of Oncology and Radiotherapy, Skopje,
Republic of Macedonia, have been involved into the study.
Patients have been selected utilising the data-base of the
National eHealth System introduced in the Republic of
Macedonia on July 1, 2013. This system fulfils all require-
ments of the international standards and covers study-
relevant information for all citizens of the Republic of
Macedonia [23, 24]. Patients recruited for the current study
have been identified as postmenopausal females with past
history of menopause defined as one year after last menstrual
period without bleeding, who have developed breast cancer
after this time (in menopause), therefore, being postmeno-
pausal breast cancer patients. These patients have been sched-
uled for visiting the University Clinic of Oncology and
Radiotherapy in Skopje, Republic of Macedonia, during the
period of time between September 20th and November 20th,
2016. Diagnosis and treatment of 67 selected breast cancer
patients with and without metastatic disease have been per-
formed in accordance with the National Guidelines for
Medical Care of Breast Cancer [25]. These guidelines corre-
spond to the international standards as stated in the govern-
mental documents cited above. The meaning of individual
questions of the FS questionnaire has been explained in
extenso by the treating oncologist and/or oncologist’s assistant
during the communication with every interviewed patient.
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The questionnaire has been self-completed by the patients
selected for the study.
Statistical analysis
For analytical and statistical evaluations, the data have been
transferred to Microsoft Excel. SPSS Statistics v20.0.0 soft-
ware (IBM, Armonk, NY, USA) has been applied. The prev-
alence of individual symptoms in groups of comparison has
been evaluated and expressed in percentage. Pearson’s chi-
square test of associations has been applied. P values below
0.05 have been considered as statistically significant.
Results
General statistics
Postmenopausal breast cancer patients (67 of total) demon-
strated the age average of 59 years against 50 years for the
reference group comprising BC-free individuals (73 of total).
The age difference was evaluated as statistically non-signifi-
cant. Postmenopausal breast cancer group demonstrated in
average the BMI = 26 (17–34). Fifty percent of this group
were overweight persons and 20% were diagnosed with dia-
betes type 2.
FS prevalence evaluated by individual symptoms
Figure 1 summarises the prevalence of individual Flammer syn-
drome symptoms (1–15) in two groups of comparison—the
BPostmenopausal breast cancer^ patients versus the reference
group of BBC-free^ individuals. Higher prevalence in postmen-
opausal breast cancer (red) has been demonstrated for altogether
11 symptoms. Statistically significant difference has been record-
ed for the symptoms 2 (feeling cold), 7 (headache), 9 (drug
sensitivity), 11 (smell perception), and 12 (body weight in early
adulthood); corresponding P values are provided in Table 1. In
this study, breast cancer patients demonstrated higher body
weight compared to the BC-free reference group; the difference
is statistically significant (P = 0.001). Although being statistically
non-significant (P= 0.470), a substantially greater prevalence has
been demonstrated for the symptom 6: Bno feeling of thirst and
drinking too little^, the BC patients, in general, have demonstrat-
ed over two times more frequently compared to the disease-free
reference group. Further, slightly higher prevalence in BC patient
cohort has been demonstrated for the symptoms 1 (cold extrem-
ities), 3 (low blood pressure), 4 (dizziness), 5 (prolonged sleep
onset), symptom 10 (pain), and symptom 15 (skin blotches in
stress). Strong plurality has been demonstrated amongst BC pa-
tients for symptoms 8 (accompanying symptoms) and 10 (pain).
Similar prevalence betweenBC patients and disease-free individ-
uals has been demonstrated for the appearance of tinnitus
(symptom 14). Slightly decreased prevalence of the symptom
13 (perfectionism) has been demonstrated for BC patients. The
results are summarised in Table 1.
Discussion
Breast cancer screening in the Republic of Macedonia
The breast screening campaign has been started in the Republic
of Macedonia in 2007 involving 19 national mammography
departments but has been criticised for only partially fulfilled
requirements and standards settled for an effective breast cancer
screening utilising mammographic approach [26]. Further, the
field-dedicated professional groups in Macedonia systematical-
ly work on the risk prediction models for breast cancer provid-
ing clear arguments considering currently existing approaches
as unsatisfactory in general and, therefore, leading to poor re-
sults and data interpretation [27]. Contextually, Macedonian
national centres have been chosen for the current multi-
centred study as being highly motivated to develop innovative
approaches in breast cancer screening, prediction and preven-
tion at both—the national and European levels.
Profile of the target patient group is typical
for the postmenopausal breast cancer cohort
The purpose of the current paper was to investigate a potential
relevance of the Flammer Syndrome for a typical postmeno-
pausal breast cancer patient cohort. Consequently, this is to
emphasise that an averaged profile of the target patient group
has been created which onmini-scale reflects the demographic
and physiologic parameters ubiquitously recorded for the cor-
responding European patient cohorts, namely
– All postmenopausal breast cancer patients treated at the
national medical centre in the Republic ofMacedonia and
involved in this study have been registered as the native
Macedonian citizens
– The age of these patients ranged between 48 and 80 years
old
Fig. 1 Evaluation of the prevalence of individual symptoms (1–15) of
the BFlammer Syndrome^ phenotype in two groups of comparison:
BBreast cancer diseased^ (Postmenopausal BC) versus BBreast cancer
free^ reference patient pool (BC-free Ref). For more details regarding
the patient recruitment and stratification—see BMaterials and Methods^.
The prevalence in each individual group is presented by percentage of
individuals who have responded to the corresponding question with
Bfrequently^ and Bsometimes^ pooled together. Responders answering
with BI do not know^ have been excluded from the overall numbers/
calculations. Question-specific notes: question 6—the ratio between BI
do not feel thirsty and drink little^ and BI feel much thirsty and drink a
lot^ has been calculated and expressed in X times; question 12—answers
Bvery slim^ and Bslim^ are pooled together and presented in percent
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35.0%
40.0%
45.0%
50.0%
55.0%
60.0%
Postmenopausal BC BC-free Ref
54.5%
43.8%
1. Do you suffer from cold hands and /or feet?
30.0%
35.0%
40.0%
45.0%
50.0%
55.0%
60.0%
65.0%
70.0%
75.0%
80.0%
Postmenopausal BC BC-free Ref
72.7%
45.2%
2. Do you feel cold when you are sing quietly or not moving for
some me?
40.0%
45.0%
50.0%
55.0%
60.0%
65.0%
Postmenopausal BC BC-free Ref
60.7%
47.8%
3. Do/did you have low blood pressure?
50.0%
55.0%
60.0%
65.0%
70.0%
75.0%
Postmenopausal BC
66.7%
63.4%
4. Do you ever feel dizzy when you suddenly stand up from a lying
or resng posion?
35.0%
40.0%
45.0%
50.0%
55.0%
60.0%
Postmenopausal BC
BC-free Ref
BC-free Ref
51.5%
41.1%
5. Do you need a relavely long me to fall asleep?
0.50
1.00
1.50
2.00
2.50
3.00
3.50
Postmenopausal BC BC-free Ref
3.00
1.31
6. How is your feeling of thirst?
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60.0%
65.0%
70.0%
75.0%
80.0%
85.0%
90.0%
Postmenopausal BC BC-free Ref
86.4%
67.1%
7. How oen do you have headache?
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
Postmenopausal BC BC-free Ref
29.7% 28.8%
8. In case you suffer from migraines aacks, do you have
accompanying symptoms (e.g. visual disturbances, transiently
altered sensaon such as cribbing in your arms or legs, etc.)?
2.0%
12.0%
22.0%
32.0%
42.0%
52.0%
62.0%
Postmenopausal BC BC-free Ref
59.0%
19.0%
9. If you have to take medicaons (other than pain killers), do you
have the feeling that you react very strongly to them and/or that
you would feel beer taking a lower dosis than that is usually
prescribed?
55.0%
60.0%
65.0%
70.0%
75.0%
Postmenopausal BC BC-free Ref
70.3%
60.3%
10. Do you suffer from any type of pain which you need painkillers
for?
15.0%
25.0%
35.0%
45.0%
55.0%
65.0%
75.0%
85.0%
Postmenopausal BC BC-free Ref
74.6%
35.6%
11. How well can you smell: Can you smell odours which other
people do not smell at all or to much lesser extent?
1.0%
11.0%
21.0%
31.0%
41.0%
51.0%
61.0%
Postmenopausal BC BC-free Ref
17.2%
58.9%
12. Were you slim at the age of 20-30 years?
Fig. 1 continued.
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– The low-weight persons created an absolute minority—
altogether, four patients with the BMI ≤ 20
– Fifty percent of all postmenopausal breast cancer patients
were overweight persons characterised by the BMI rang-
ing between 26 and 34
– Twenty percent of all postmenopausal breast cancer pa-
tients investigated in the current study have been diag-
nosed with diabetes type 2.
– A big portion of this patient pool has been diagnosed with
the metastatic breast cancer.
Body shape and postmenopausal breast cancer risk
In consensus with the results presented here, it has been clear-
ly demonstrated that both in Europe and in the USA, women
aged 60 and above are more likely to be overweight or obese
than any other age groups [28, 29]. Overweight, obesity and
diabetes mellitus type 2 are the risk factors well described in
the context of the oestrogen-receptor-positive breast cancer
prevalence specifically in postmenopausal women [30–33].
However, it does not explain the following facts. Firstly, far
not all postmenopausal breast cancer patients are overweight,
obese and or diagnosed with diabetes mellitus type 2; in the
patient group investigated here, the averaged BMI was 26 and
exactly 50% of patients overweight. Another 50% demon-
strated normal body weight by BMI ≤ 25, however, being
breast cancer diseased. Secondly, breast cancer is a chronic
pathology developing over years or even decades of life.
That means that the pre/cancer lesions were developing during
premenopausal period of life, when the body weight was av-
erage. This seems to be the case in our study: about 90% of all
respondents of the postmenopausal breast cancer group have
noted that, although being not slim in contrast to the breast
cancer-free reference group (the difference has been found
significant, P = 0.001), their body weight was within the nor-
mal range at the young age. Indeed, some recent studies dem-
onstrate adverse effects of long-term adult weight gain for
postmenopausal breast cancer [32]. This might justify the ap-
pearance of the postmenopausal breast cancer for about 50%
of our target patient cohort. However, there is no currently
provided explanation for another 50% of these patients from
view point of risks by overweight, obesity and diabetes
mellitus type 2 in elderly.
What is new in the concepts presented here?
The results presented in our current stud clearly demonstrate
that postmenopausal breast cancer cannot be explained solely
by appearance of individual risk factors such as increased
BMI, fluctuating body weight and/or lifetime body size. It is
a multi-factorial systemic disease with a great number of con-
tributing factor which should be obligatory considered in the
context of individual patient profiles for reliable prediction
and prognosis. What is new in the concepts presented here?
50.0%
55.0%
60.0%
65.0%
70.0%
75.0%
80.0%
Postmenopausal BC BC-free Ref
63.3%
67.1%
13. If you would judge your atude (e.g. in job), would you
recognise a tendency towards perfeconism?
30.0%
32.0%
34.0%
36.0%
38.0%
40.0%
42.0%
44.0%
Postmenopausal BC BC-free Ref
37.5% 37.0%
14. Do you noce ringing in your ears (nnitus) from me to
me?
25.0%
27.0%
29.0%
31.0%
33.0%
35.0%
37.0%
39.0%
Postmenopausal BC BC-free Ref
34.9%
32.9%
15. Have you noced reversible blotches (white or red) on your
skin when you were very excited or angry (e.g. in stress)?
Fig. 1 continued.
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First of all, it is a systemic multi-contextual consideration of
individual parameters. Just an example: since years, headache is
a strongly disputed symptom regarding its breast cancer rele-
vance. So far, in general, the dedicated studies have consider
unilaterally the hormonal aspects of headache concluding that
falling oestrogen levels which causes migraine are associated
with a decreased risk of breast cancer, particularly amongst
ER+/PR+ ductal and lobular carcinomas [34, 35]. In contrast,
results presented here demonstrate significantly higher preva-
lence (P = 0.008) of headache in the postmenopausal breast
cancer patient group versus BC-free individuals. Certainly,
whether prevalent or not, headache/migraine attacks is an indi-
cator for severe pathological events which should be deeply
analysed in a multi-parametric context. This is exactly what
our current study did demonstrating that besides the prevalent
headache, postmenopausal breast cancer patients investigated
Table 1 Symptoms of the BFlammer Syndrome^ recorded in
BPostmenopausal breast cancer patients^ versus BBreast cancer free
individuals^ groups of comparison; the table summarises the results
demonstrated in Fig. 1; the following system is employed: B+^ means
higher prevalence of the corresponding symptom (above the lowest
average of the groups of comparison); B−^ means lower prevalence of
the corresponding symptom (lowest average and below it)
Nr. “Flammer 
Syndrome”
symptoms
Postmenopausal BC pa ents BC-free
individuals
Prevalence Significance
P value 
Prevalence
1 Cold hands + 0.207 -
2 Feeling cold + 0.001 -
3 Low blood 
pressure
+ 0.144 -
4 Dizziness + 0.695 -
5 Sleep onset + 0.218 -
6 Thirst + 0.470 -
7 Headache + 0.008 -
9 Drug sensi vity + 0.001 -
10 Pain + 0.219 -
11 Smell percep on + 0.001 -
15 Skin blotches + 0.802 -
8 Accompanying
symptoms 
= 0.906 =
12 Low body weight 
in early adulthood
- 0.001 +
13 Perfec onism - 0.647 +
14 Tinnitus = 0.951 =
∑ criteria
11+ 
2=
2-
5 significant 2+
2=
11-
The level of significance is noted. P values below 0.05 are considered statistically significant and marked in red colour (symptoms 2, 7, 9, 11 and 12).
Eleven symptoms united within the green-marked cluster demonstrate the prevalence increased in BC. The prevalence of four symptoms united within
the yellow-marked cluster is either similar or decreased in BC
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demonstrate a pronounced vascular dysregulation and conse-
quently systemic hypoxic effects linked to the cardiovascular
component (symptoms 1 Bcold hands^ and 2 Bfeeling cold^),
altered sense regulation (symptom 11 Bsmell perception^) and
potential body dehydration (symptom 6 Bdo not feel thirsty and
drink too little^). All of them are highly relevant for both—
breast cancer progression and headache.
New interpretation of the BSeed and Soil^ theory
of metastasis in breast cancer
Another conceptual novelty presented here is a new interpre-
tation of the BSeed and Soil^ theory of metastasis in breast
cancer. It is important to emphasise that the responses given
towards individual questions (see Fig. 1) refer to the health
condition and behaviour of the patients considered in a long-
term manner but not restricted to the period of time dedicated
to the treatment of breast cancer and metastatic disease.
Consequently, the results clearly support the hypothesis pre-
sented [4, 5] proposing that a strong epi/genetic predisposition
of individuals at risk to form the systemic hypoxic pre-
metastatic niches can be established a long time before the
breast malignancy is clinically manifested. FS phenotype acts
over several life decades contributing to pronounced vascular
dysregulation and systemic hypoxic effects which, in turn,
create the fertile microenvironment (Bsoil^) in distant organs
for the circulating tumour cells (CTC, Bseeds^) once they
appear in the blood stream. This new concept explains well
why and how Bmetastatic inefficiency^ [36] may turn into
aggressive metastatic disease. It is known that in manifested
oncologic diseases, less than 1% of all disseminated and cir-
culated tumour cells have a potential to form secondary and
distanced tumours (metastatic diseases)—the phenomenon
known as the metastatic inefficiency [36]. However, in case
of the chronic systemic hypoxia, fertile microenvironment
(soil) is highly supportive for both the initial tumour develop-
ment in the breast tissue and aggressive metastatic disease via
CTC (seeds) domesticated and progressing in distant organs
which are systemically affected by hypoxic effects as well [3,
5]. In the new concept, the pre-metastatic niches (soil) are
created by a systemic hypoxia a long time before the breast
malignancy is clinically manifested.
Study limitation
The main limitation of the presented study is a relatively low
number of the interviewed patients that hindered more precise
patient stratification into corresponding subgroups towards
disease-relevant parameters such as collateral pathologies
and detailed characterisation of the metastatic disease diag-
nosed in a certain portion of the BC patients investigated,
amongst others. This issue is considered for designing the
follow-up projects.
Conclusion and outlook
Current multi-centred study highlights new complex mecha-
nisms of the development and progression of the postmeno-
pausal breast cancer. Innovative concepts are presented which
argue for more effective predictive and preventive approaches
being well justified in view of the clusters of the Flammer
syndrome—symptoms analysed here and demonstrated as
highly prevalent in the postmenopausal breast cancer versus
BC-free individuals. Regarding the next steps, we propose to
perform the dedicated large-scale studies to validate the results
introduced by this pioneer multi-centred pilot project. Follow-
up studies may consider to stratify the patient subgroups
utilising individual molecular biological profiles and comple-
mentary questionnaires related to the known breast cancer risk
factors. Family doctors (GPs) should be obligatory involved in
the follow-up studies for the educational purposes, creation
and application of innovative screening programmes utilising
the knowledge collected in the current project.
BC breast cancer, BMI body mass index, CTC circulating
tumour cells, FIA fibro-adenoma, FS Flammer syndrome,
GPs general practitioners (family doctors).
Acknowledgements The authors thank Prof. Dr. Josef Flammer,
University of Basel, for his valuable recommendations during the prepa-
ration and performance of the actual multi-centred project.
Authors’ contributions Olga Golubnitschaja is the project coordinator
who has created the main scientific ideas and hypotheses presented in the
manuscript; she has drafted the manuscript. Ivica Smokovski has coordi-
nated the research, patient recruitment and data analysis performed in the
Republic of Macedonia. Milan Risteski has performed the recruitment of
all postmenopausal breast cancer patients and interviewed these patients
in the Republic of Macedonia. Pavol Zubor has coordinated the research,
patient recruitment and data analysis performed in Slovakia, analysed the
corresponding patient data-base, selected breast cancer-free individuals
for the reference group, and provided the final data from interviewing this
group. Jiri Polivka Jr. has performed complete statistical analysis.
Vincenzo Costigliola has contributed with his expertise in the European
standards for primary care. Katarzyna Konieczka has contributed by the
expertise in the Flammer syndrome. All the authors have read and ap-
proved the final manuscript.
Compliance with ethical standards All procedures performed in the
current study involving human participants were in accordance with the
ethical standards of the institutional and/or national research committee
and with the 1964 Helsinki declaration and its later amendments or com-
parable ethical standards.
Competing interests The authors declare that they have no competing
interests.
Funding This multi-centred study has been supported by the following
organisations: European Association for Predictive, Preventive and
Personalised Medicine, EPMA, Brussels, Belgium; Schwickert
Foundation, Switzerland; and the National Sustainability Program I
(NPU I) Nr. LO1503, Ministry of Education Youth and Sports,
Czech Republic and MH CZ-DRO (Faculty Hospital in Plzen-FNPl,
00669806).
EPMA Journal
Author's personal copy
References
1. Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M,
Costigliola V, Grech G. Breast cancer epidemic in the early 21st
century: evaluation of risk factors, cumulative questionnaires and
recommendations for preventive measures. Tumor Biol.
2016;37(10):12941–57. doi:10.1007/s13277-016-5168-x.
2. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A,
Ferlay J, Renehan AG, Forman D, Soerjomataram I. Recent trends
in incidence of five common cancers in 26 European countries since
1988: analysis of the European cancer observatory. Eur J Cancer.
2015;51(9):1164–87. doi:10.1016/j.ejca.2013.09.002.
3. Golubnitschaja O. Feeling cold and other underestimated symp-
toms in breast cancer: anecdotes or individual profiles for advanced
patient stratification? EPMA J 2017; 8(1):17–22. doi:10.1007/
s13167-017-0086-6.
4. Zubor P, GondovaA, Polivka J Jr, Kasajova P, Konieczka K,Danko
J, Golubnitschaja O. Breast cancer and Flammer syndrome: any
symptoms in common for prediction, prevention and personalised
medical approach? EPMA J. 2017; doi:10.1007/s13167-017-0089-
3.
5. Bubnov R, Polivka J Jr, Zubor P, Koniczka K, Golubnitschaja O.
BPre-metastatic niches^ in breast cancer: are they created by or prior
to the tumour onset? BFlammer syndrome^ relevance to address the
question. EPMA J. 2017; doi:10.1007/s13167-017-0092-8.
6. Kokolus K, Hing CC, Repasky EA. Feeling too hot or cold after
breast cancer: is it just a nuisance or a potentially important prog-
nostic factor? Int J Hyperth. 2010;26(7):662–80. doi:10.3109/
02656736.2010.507235.
7. Daniels LB, Maisel AS. Cardiovascular biomarkers and sex: the
case for women. Nat Rev Cardiol. 2015;12(10):588–96. doi:10.
1038/nrcardio.2015.105.
8. Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov
RV, Goncharenko VM, Lushchyk U, Grech G, Konieczka K.
Flammer syndrome and potential formation of pre-metastatic
niches: a multi-centred study on phenotyping, patient stratification,
prediction and potential prevention of aggressive breast cancer and
metastatic disease. EPMA J. 2016;7(Suppl 1):9,A25. doi:10.1186/
s13167-016-0054-6.
9. Cox TR, Rumney RM, Schoof EM, Perryman L, Hoye AM,
Agrawal A, et al. The hypoxic cancer secretome induces pre-
metastatic bone lesions through lysyl oxidase. Nature. 2015;522:
106–10. doi:10.1038/nature14492.
10. Vanharanta S. A hypoxic ticket to the bone metastatic niche. Breast
Cancer Res. 2015;17(1):122. doi:10.1186/s13058-015-0635-7.
11. Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino
A, Golubnitschaja O, Erb C, Reitsamer HA, Kida T, Kurysheva N,
Yao K. Flammer syndrome. EPMA J. 2014;5(1):11. doi:10.1186/
1878-5085-5-11.
12. Yeghiazaryan K, Flammer J, Orgül S, Wunderlich K,
Golubnitschaja O. Vasospastic individuals demonstrate significant
similarity to glaucoma patients as revealed by gene expression
profiling in circulating leukocytes. Mol Vis. 2009;15:2339–48.
13. Flammer J, Konieczka K, Flammer AJ. The primary vascular dys-
regulation syndrome: implications for eye diseases. EPMA J.
2013;4(1):14. doi:10.1186/1878-5085-4-14.
14. Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecu-
lar profiling in blood of healthy vasospastic individuals: clue to
targeted prevention as personalised medicine to effective costs.
EPMA J. 2010;1(2):263–72. doi:10.1007/s13167-010-0032-3.
15. Golubnitschaja O, Yeghiazaryan K, Flammer J. Key molecular
pathways affected by glaucoma pathology: is predictive diagnosis
possible? EPMA J. 2010;1(2):237–44. doi:10.1007/s13167-010-
0031-4.
16. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D,
Braun M, Debald M, Kuhn W, Schild HH. Risk assessment,
disease prevention and personalised treatments in breast can-
cer: is clinically qualified integrative approach in the hori-
zon? EPMA J. 2013;4(1):6. doi:10.1186/1878-5085-4-6.
17. Konieczka K, Choi HJ, Koch S, Schoetzau A, Küenzi D, Kim DM.
Frequency of symptoms and signs of primary vascular dysregula-
tion in Swiss and Korean populations. Klin Monatsbl Augenheilkd.
2014;231(4):344–7. doi:10.1055/s-0034-1368239.
18. Konieczka K, Fränkl S. Primäre vaskuläre Dysregulation und
Glaukom (Primary vascular dysregulation and glaucoma). Z prakt
Augenheilkd. 2013;34:207–15.
19. Konieczka K, Koch S, Binggeli T, Schoetzau A, Kesselring
J. Multiple sclerosis and primary vascular dysregulation
(Flammer syndrome). EPMA J. 2016;7:13. doi:10.1186/
s13167-016-0062-6.
20. KonieczkaK, Koch S, SchoetzauA, TodorovaMG. Increased prev-
alence of Flammer syndrome in patients with retinitis Pigmentosa.
Klin Monatsbl Augenheilkd. 2016;233(4):448–52. doi:10.1055/s-
0041-111802.
21. Konieczka K, Todorova MG, Chackathayil TN, Henrich PB.
Cilioretinal artery occlusion in a young patient with flammer syn-
drome and increased retinal venous pressure. Klin Monatsbl
Augenheilkd. 2015;232(4):576–8. doi:10.1055/s-0035-1545774.
22. Konieczka K, Flammer J, Sternbuch J, Binggeli T, Fraenkl S.
Leber’s hereditary optic neuropathy, normal tension glaucoma,
and Flammer syndrome: long term follow-up of a patient. Klin
Monatsbl Augenheilkd. 2017; doi:10.1055/s-0042-119564.
23. Health Consumer Powerhouse. Eurohealth Consumer Index
Report, 2014. Taby, Sweden: Health Consumer Powerhouse.
http://www.healthpowerhouse.com/files/EHCI_2014/EHCI_
2014_report.pdf. Accessed on 22 Jan 2017.
24. Smokovski I, Milenkovic T, Trapp C, Mitov A. Diabetes Care in
Republic of Macedonia: challenges and opportunities. Annals of
Global Health. 2015;81(6):792–802. doi:10.1016/j.aogh.2015.12.
017.
25. Ministry of Health of Republic of Macedonia. National guidelines
for medical care of breast cancer, 2015. http://zdravstvo.gov.mk/
wp-content/uploads/2015/08/Rak-na-dojka.pdf. Accessed on 22
Jan 2017.
26. Gershan V, Antevska-Grujoska S. Performance of mammography
equipment in the Macedonian breast screening campaign
2008/2009. Radiat Prot Dosim. 2011;147(1–2):187–91. doi:10.
1093/rpd/ncr290.
27. Gjorgov NA. Breast cancer risk assessments to barrier contracep-
tion exposure. A new approach. Prilozi. 2009;30(1):217–32.
28. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of child-
hood and adult obesity in the United States, 2011–2012. JAMA.
2014;311(8):806–14. doi:10.1001/jama.2014.732.
29. Overweight and obesity—BMI statistics [database on the Internet].
Eurostat. http://ec.europa.eu/eurostat/statistics-explained/index.
php/Overweight_and_obesity_-_BMI_statistics Accessed on 28
March 2017.
30. Arnold M, Freisling H, Stolzenberg-Solomon R, Kee F,
O'Doherty MG, Ordóñez-Mena JM, Wilsgaard T, May AM,
Bueno-de-Mesqui ta HB, Tjønneland A, Orfanos P,
Trichopoulou A, Boffetta P, Bray F, Jenab M, Soerjomataram
I, CHANCES consortium. Overweight duration in older adults
and cancer risk: a study of cohorts in Europe and the United
States. Eur J Epidemiol. 2016;31(9):893–904. doi:10.1007/
s10654-016-0169-z.
31. Horn-Ross PL, Canchola AJ, Bernstein L, Neuhausen SL, Nelson
DO, Reynolds P. Lifetime body size and estrogen-receptor-positive
breast cancer risk in the California teachers study cohort. Breast
Cancer Res. 2016;18(1):132. doi:10.1186/s13058-016-0790-5.
EPMA Journal
Author's personal copy
32. Rosner B, Eliassen AH, Toriola AT, Chen WY, Hankinson SE,
Willett WC, Berkey CS, Colditz GA. Weight and weight changes
in early adulthood and later breast cancer risk. Int J Cancer.
2017;140(9):2003–14. doi:10.1002/ijc.30627.
33. Cebioglu M, Schild HH, Golubnitschaja O. Cancer predisposition
in diabetics: risk factors considered for predictive diagnostics and
targeted preventive measures. EPMA J. 2010;1(1):130–7. doi:10.
1007/s13167-010-0015-4.
34. Mathes RW,Malone KE, Daling JR, Davis S, Lucas SM, Porter PL,
Li CI. Migraine in postmenopausal women and the risk of invasive
breast cancer. Cancer Epidemiol Biomark Prev. 2008;17(11):3116–
22. doi:10.1158/1055-9965.EPI-08-0527.
35. Li CI, Mathes RW, Bluhm EC, Caan B, Cavanagh MF,
Chlebowski RT, Michael Y, O’Sullivan MJ, Stefanick ML,
Prentice R. Migraine history and breast cancer risk among
postmenopausal women. J Clin Oncol. 2010;28(6):1005–10.
doi:10.1200/JCO.2009.25.0423.
36. Redig AJ, McAllister SS. Breast cancer as a systemic disease: a
view of metastasis. J Intern Med. 2013;274(2):113–26. doi:10.
1111/joim.12084.
EPMA Journal
Author's personal copy
